Rogerio Lilenbaum, MD, Discusses Immunotherapy and Targeted Therapy for Lung Cancer

News
Article

Rogerio Lilenbaum, MD, talked about the state of lung cancer in regards to immunotherapy and targeted therapy at the 17th Annual Winter Lung Conference in Miami Beach, Florida.

Rogerio Lilenbaum, MD, discussed the ways in which immunotherapy and targeted therapy have changed the study of lung cancer. At the 17th Annual Winter Lung Conference, Lilenbaum described how immunotherapy has improved quality of life for patients, while also allowing them to live longer.

Transcription:

I think immunotherapy has revolutionized the way we think about lung cancer and other solid tumors and other hematologic malignancies. Immunotherapy has changed the face of this disease and has allowed patients to live not only much longer than they used to live on more traditional treatments, but they also live a better life.

Immunotherapy has fulfilled its promise to prolong life and maintain and improve quality of life. A pursuit, by the way, that is decades old, and finally came through in the past 5 years. It’s really an incredible revolution. It’s akin to what happened in the early 2000s when the molecular aberrations were discovered, and targeted agents came into the market and again changed the face of this disease.

The difference between targeted therapy and immunotherapy is that you can use immunotherapy in a much larger percentage of patients. Targeted therapy remains somewhat limited to a percentage of patients who have the markers.

Recent Videos
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Related Content